Encysive’s Thelin Gets EU Nod Ahead Of U.S.
EU marketing authorization of the pulmonary arterial hypertension treatment follows Encysive’s receipt of a second “approvable” letter for sitaxentan sodium from FDA.
EU marketing authorization of the pulmonary arterial hypertension treatment follows Encysive’s receipt of a second “approvable” letter for sitaxentan sodium from FDA.